Cell therapy (CAR-T) · Kills target cells, directed at CD22 · developed by Sana Biotechnology
SC262 is an allogeneic CAR T-cell therapy made from CD4+ and CD8+ T-lymphocytes engineered with a chimeric antigen receptor specific for CD22, with MHC class I and II expression disrupted and CD47 expressed to reduce immune rejection. It is designed to recognize and kill CD22-expressing B-cell tumor cells and is studied in non-Hodgkin's lymphoma and large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06285422 | Phase 1 | Non Hodgkin's Lymphoma | Active not recruiting | SANA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Large B-cell LymphomaNon Hodgkin's Lymphoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the SANA page.
See SANA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SANA catalysts and pipeline →